Ovarian Cancer : Status, Size, Share, Trends and Application 2017
ResearchMoz presents professional and in-depth study of "Ovarian Cancer-Pipeline Insights, 2016".
DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries. It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK. The report provides the in-depth analysis of the pipeline assets across the Ovarian Cancer. The Report gives insights on 225+ products. It also includes around 185+ companies which are active in this field. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Ovarian Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Ovarian Cancer. These days companies are focusing on the Targeted Therapy for cancer. Roches Pertuzumab, Merck Avelumab and Morphoteks Farletuzumab is the monoclonal antibody in Phase III stage competing against the other small molecules in development. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. These are in preregistration stage of development.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=745900
Table of Contents
Ovarian Cancer Overview
Signs and symptoms
Diagnosis
Treatment
Pipeline Therapeutics
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=745900
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries. It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK. The report provides the in-depth analysis of the pipeline assets across the Ovarian Cancer. The Report gives insights on 225+ products. It also includes around 185+ companies which are active in this field. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Ovarian Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Ovarian Cancer. These days companies are focusing on the Targeted Therapy for cancer. Roches Pertuzumab, Merck Avelumab and Morphoteks Farletuzumab is the monoclonal antibody in Phase III stage competing against the other small molecules in development. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. These are in preregistration stage of development.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=745900
Table of Contents
Ovarian Cancer Overview
Signs and symptoms
Diagnosis
Treatment
Pipeline Therapeutics
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=745900
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://latestmedicalrelatedresearchreport.blogspot.in/
Comments
Post a Comment